The clinical characteristics and therapy response of patients with acquired pure red cell aplasia

Figures & data

Table 1. Peripheral blood and bone marrow teats of acquired PRCA patients.

	n	mean ± SD	P-value
Hb (g/L)
Total	53	63.96 ± 16.91
Idiopathic	30	62.22 ± 14.84	.45
Secondary	23	66.00 ± 19.19
RBC (×10^12/L)
Total	53	2.06 ± 0.62
Idiopathic	30	1.90 ± 0.49	.08
Secondary	23	2.22 ± 0.71
Ret (%)
Total	53	0.26 ± 0.21
Idiopathic	30	0.34 ± 0.23	.03
Secondary	23	0.20 ± 0.16
Ret (×10^9/L)
Total	53	4.89 ± 4.03
Idiopathic	30	6.15 ± 4.45	.05
Secondary	23	3.75 ± 3.29
Erythroid proportion (sternum, %)
Total	43	3.63 ± 5.56
Idiopathic	23	5.80 ± 6.86	.04
Secondary	20	1.12 ± 1.20
Erythroid proportion (iliac, %)
Total	53	1.97 ± 3.12
Idiopathic	30	2.46 ± 3.54	.22
Secondary	23	1.33 ± 2.39

Table 2. Iron tests of acquired PRCA patients.

	n	mean ± SD	P-value
Fer(ng/mL)
Total	49	784.02 ± 643.03
Idiopathic	26	613.11 ± 558.49	.04
Secondary	23	977.22 ± 688.60
SI (μmol/L)
Total	32	30.08 ± 12.37
Idiopathic	17	36.14 ± 14.65	.36
Secondary	15	40.26 ± 9.16
TIBC (μmol/L)
Total	32	49.44 ± 18.24
Idiopathic	17	48.07 ± 20.35	.66
Secondary	15	50.89 ± 16.25
UIBC (μmol/L)
Total	32	12.64 ± 16.67
Idiopathic	17	13.64 ± 16.26	.72
Secondary	15	11.51 ± 17.59
TRF (mg/μL)
Total	32	185.59 ± 54.53
Idiopathic	17	189.88 ± 63.16	.64
Secondary	15	180.73 ± 44.47

Table 3. The response rate of therapy in acquired PRCA patients.

	n	CR (%)	P-value
Total	41	68.29%
Pathogenesis
Idiopathic PRCA	24	58.33%	.10
Secondary PRCA	17	82.35%
EPO level
≤400U/L	9	88.89%	.04
> 400U/L	19	57.14%
Fer level
≤200(ng/ml)	12	91.67%	.03
> 200(ng/ml)	28	57.10%
Therapy
CS	9	55.56%	.43
CS + CsA	32	71.86%

Figure 1. The recovery time of hemoglobin and reticulocyte in acquired PRCA patients. (A) Recovery time of idiopathic and secondary PRCA group. Groups 1, 2 and 3 were termed as time of reticulocyte recovered to normal, PR and CR, respectively. (B) Recovery time of patients with different EPO level. Groups 1, 2 and 3 were termed as time of reticulocyte recovered to normal, PR and CR, respectively.